Literature DB >> 19091615

Risk factors for feline immunodeficiency virus antibody test status in Cats Protection adoption centres (2004).

Jane K Murray1, Margaret A Roberts, Elizabeth Skillings, Lisa D Morrow, Timothy J Gruffydd-Jones.   

Abstract

A study was carried out to determine the prevalence of feline immunodeficiency virus (FIV) within a population of cats entering 10 UK adoption centres run by Cats Protection. All cats entering the adoption centres during 2004 were tested for FIV using a rapid enzyme immunoassay antibody test. The overall prevalence of positive test results was 3.1% (95% confidence intervals (CI) 2.7-3.5%), whilst the prevalence at different adoption centres varied from 0.8% (95% CI 0.1-1.5%) to 6.7% (95% CI 4.9-8.5%). Results of the multivariable logistic regression analysis showed that male cats, stray/feral cats and cats in poor health were at a greater risk of testing positive for FIV than female cats, cats that were relinquished by an owner and cats that were in good/fair health, respectively. No evidence was found for an association between neuter status and FIV test results. This study may help to identify cats that are relinquished to rescue centres with an increased risk of FIV for routine FIV testing.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19091615     DOI: 10.1016/j.jfms.2008.11.001

Source DB:  PubMed          Journal:  J Feline Med Surg        ISSN: 1098-612X            Impact factor:   2.015


  2 in total

1.  Human influences shape the first spatially explicit national estimate of urban unowned cat abundance.

Authors:  Jennifer L McDonald; Elizabeth Skillings
Journal:  Sci Rep       Date:  2021-10-28       Impact factor: 4.379

2.  Relevance of feline interferon omega for clinical improvement and reduction of concurrent viral excretion in retrovirus infected cats from a rescue shelter.

Authors:  Solange Gil; Rodolfo O Leal; Ana Duarte; David McGahie; Nuno Sepúlveda; Inês Siborro; Joana Cravo; Clara Cartaxeiro; Luís M Tavares
Journal:  Res Vet Sci       Date:  2012-10-31       Impact factor: 2.534

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.